(84 days)
Not Found
Yes
The device description explicitly states that it "utilizes deep learning technologies" and "analyzes cases using an artificial intelligence algorithm".
No
The device is a software workflow tool designed to aid in prioritizing the clinical assessment of adult non-contrast head CT cases with features suggestive of acute intracranial hemorrhage. It identifies suspected findings and makes output available for worklist prioritization or triage. It does not provide any treatment or therapy.
No
The device is a software workflow tool designed to aid in prioritizing the clinical assessment of adult non-contrast head CT cases with features suggestive of acute intracranial hemorrhage. It is explicitly stated that its results are "not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out hemorrhage or otherwise preclude clinical assessment of CT cases," indicating it is for workflow prioritization rather than direct diagnosis.
Yes
The device description explicitly states "Accipiolx is a software device designed to be installed within healthcare facility radiology networks". It processes data received from other devices (MICD) and outputs results to a PACS/workstation, without mentioning any accompanying hardware components included as part of the device itself.
Based on the provided information, Accipiolx is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information about a person's health.
- Accipiolx Function: Accipiolx analyzes medical images (CT scans) of the head. It does not analyze biological specimens.
- Intended Use: The intended use is to aid in prioritizing the clinical assessment of head CT cases, not to diagnose a condition based on laboratory analysis of a specimen.
Therefore, Accipiolx falls under the category of a medical device, specifically a software device that processes medical images, but it is not an IVD.
No
The letter does not state that the FDA has reviewed and approved or cleared a Predetermined Change Control Plan (PCCP) for this specific device.
Intended Use / Indications for Use
Accipiolx is a software workflow tool designed to aid in prioritizing the clinical assessment of adult non-contrast head CT cases with features suggestive of acute intracranial hemorrhage in the acute care environment. Accipiolx analyzes cases using an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage.
Accipiolx is not intended to direct attention to specific portions of an image or to anomalies other than acute intracranial hemorrhage. Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out hemorrhage or otherwise preclude clinical assessment of CT cases.
Product codes
QAS
Device Description
Accipiolx is a software device designed to be installed within healthcare facility radiology networks to identify and prioritize non-contrast head CT (NCCT) scans based on algorithmically-identified findings of acute intracranial hemorrhage (alCH). The device, which utilizes deep learning technologies, facilitates prioritization of CT scans containing findings of alCH. Accipiolx receives CT scans identified by the Accipio Agent or other compatible Medical Image Communications Device (MICD), processes them using algorithmic methods involving execution of multiple computational steps to identify suspected presence of alCH, and generates a results file to be transferred by the Accipio Agent or a similar MICD device for output to a PACS system or workstation for worklist prioritization.
Accipiolx works in parallel to and in conjunction with the standard care of workflow. After a CT scan has been performed, a copy of the study is automatically retrieved and processed by Accipiolx. The device performs identification and classification of objects consistent with alCH, and provides a case-level indicator which facilitates prioritization of cases with potential acute hemorrhagic findings for urgent review.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Yes
Input Imaging Modality
Non-Contrast head CT
Anatomical Site
Head
Indicated Patient Age Range
Adult patients (21 years of age and older)
Intended User / Care Setting
Hospital networks and trained clinicians, Acute care
Description of the training set, sample size, data source, and annotation protocol
The subject Accipiolx, like its predicate device, was developed using a training CT cases collected from multiple institutions and CT manufacturers. This training process included pilot development, optimization of object and feature identification, algorithmic training and selection/optimization of thresholds above which cases are considered positive.
Description of the test set, sample size, data source, and annotation protocol
Analysis of 360 newly tested cases collected from multiple sites across 17 US states demonstrated device Sensitivity and Specificity of 97% (95% Cl: 92.8%) and 93% (95% Cl: 88.6% - 96.6%), respectively.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing was conducted using the same approach as that used for the predicate device. MaxQ AI conducted a retrospective study to test the clinical performance of Accipiolx in processing non-contrast head CT cases with a high or low probability of ICH. Performance of the device was analyzed based on validation testing results that were compared to the predefined performance qoals.
- Analysis of 360 newly tested cases collected from multiple sites across 17 US states demonstrated device Sensitivity and Specificity of 97% (95% Cl: 92.8%) and 93% (95% Cl: 88.6% - 96.6%), respectively.
- Sensitivity for intra-axial and extra-axial hemorrhages was 100% (95% Cl: 96.6% 100%) and 92% (95% Cl: 82.7% - 96.9%), respectively. Although the Sensitivity observed in the extra-axial subgroup was lower compared to the intra-axial subgroup, the result was still notably high, considering the fact that extra-axial hemorrhages are known to be more difficult for accurate assessment among radiologists.
- The average per-case processing time (confirmatory secondary endpoint) was 1.17 minutes (95% Cl: 1.16 - 1.18 minutes), demonstrating that when using the subject Accipiolx for alCH prioritization, the intended users will have improved benefit in time saving compared to the predicate device.
- Analysis of additional accuracy parameters, tested as secondary endpoints, demonstrated NPV and PPV of 99.8% (95% Cl: 99.7% - 100%) and 43.3% (95% - 53%), respectively, The very high NPV result reflects relatively very low probability of false positive results given by Accipiolx.
These results exceeded the predefined performance goals and demonstrated improved clinical performance, which is substantially equivalent to the predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity- 97% (95% Cl: 92.8% - 98.8%), Specificity- 93% (95% Cl: 88.6% - 96.6%), Processing time - 1.17 minutes (95% Cl: 1.16 - 1.18 minutes), NPV - 99.8% (95% Cl: 99.7% - 100%), PPV - 43.3% (95% - 53%)
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.2080 Radiological computer aided triage and notification software.
(a)
Identification. Radiological computer aided triage and notification software is an image processing prescription device intended to aid in prioritization and triage of radiological medical images. The device notifies a designated list of clinicians of the availability of time sensitive radiological medical images for review based on computer aided image analysis of those images performed by the device. The device does not mark, highlight, or direct users' attention to a specific location in the original image. The device does not remove cases from a reading queue. The device operates in parallel with the standard of care, which remains the default option for all cases.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Design verification and validation must include:
(i) A detailed description of the notification and triage algorithms and all underlying image analysis algorithms including, but not limited to, a detailed description of the algorithm inputs and outputs, each major component or block, how the algorithm affects or relates to clinical practice or patient care, and any algorithm limitations.
(ii) A detailed description of pre-specified performance testing protocols and dataset(s) used to assess whether the device will provide effective triage (
e.g., improved time to review of prioritized images for pre-specified clinicians).(iii) Results from performance testing that demonstrate that the device will provide effective triage. The performance assessment must be based on an appropriate measure to estimate the clinical effectiveness. The test dataset must contain sufficient numbers of cases from important cohorts (
e.g., subsets defined by clinically relevant confounders, effect modifiers, associated diseases, and subsets defined by image acquisition characteristics) such that the performance estimates and confidence intervals for these individual subsets can be characterized with the device for the intended use population and imaging equipment.(iv) Stand-alone performance testing protocols and results of the device.
(v) Appropriate software documentation (
e.g., device hazard analysis; software requirements specification document; software design specification document; traceability analysis; description of verification and validation activities including system level test protocol, pass/fail criteria, and results).(2) Labeling must include the following:
(i) A detailed description of the patient population for which the device is indicated for use;
(ii) A detailed description of the intended user and user training that addresses appropriate use protocols for the device;
(iii) Discussion of warnings, precautions, and limitations must include situations in which the device may fail or may not operate at its expected performance level (
e.g., poor image quality for certain subpopulations), as applicable;(iv) A detailed description of compatible imaging hardware, imaging protocols, and requirements for input images;
(v) Device operating instructions; and
(vi) A detailed summary of the performance testing, including: test methods, dataset characteristics, triage effectiveness (
e.g., improved time to review of prioritized images for pre-specified clinicians), diagnostic accuracy of algorithms informing triage decision, and results with associated statistical uncertainty (e.g., confidence intervals), including a summary of subanalyses on case distributions stratified by relevant confounders, such as lesion and organ characteristics, disease stages, and imaging equipment.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym and name on the right. The FDA part of the logo is in blue, with the acronym in a square and the full name, "U.S. Food & Drug Administration," written out next to it.
MaxQ Al Ltd. % Joshua Schulman, Ph.D. Vice President, Clinical, Regulatory and Quality Affairs 96 Yigal Alon Street, 1st Floor Tel Aviv, 6789140 ISRAEL
August 7, 2020
Re: K201310
Trade/Device Name: Accipiolx Regulation Number: 21 CFR 892.2080 Regulation Name: Radiological computer aided triage and notification software Regulatory Class: Class II Product Code: QAS Dated: May 15, 2020 Received: May 15, 2020
Dear Dr. Schulman:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
1
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
For
Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
510(k) Number (if known)
K201310
Device Name
Accipiolx
Indications for Use (Describe)
Accipiolx is a software workflow tool designed to aid in prioritizing the clinical assessment of adult non-contrast head CT cases with features suggestive of acute intracranial hemorrhage in the acute care environment. Accipiolx analyzes cases using an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage.
Accipiolx is not intended to direct attention to specific portions of an image or to anomalies other than acute intracranial hemorrhage. Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out hemorrhage or otherwise preclude clinical assessment of CT cases.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| X Prescription Use (Part 21 CFR 801 Subpart D) | |
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY
MaxQ AI's Accipiolx
Submitter
MaxQ AI Ltd. 96 Yigal Alon Street, Tel Aviv, Israel 6789140 Tel: +1-617-765-0333 Contact Person: Josh Schulman, Ph.D.
Date Prepared: May 15, 2020
Name of Device: Accipiolx
Common or Usual Name/ Classification Name:
Radiological Computer-Assisted Triage and Notification Software
Regulatory Class: Class II
Regulatory Classification and Product Code: 21 C.F.R. § 892.2080; QAS
Predicate Device: Accipiolx, K182177, Manufactured by MaxQ Al
Device Description
Accipiolx is a software device designed to be installed within healthcare facility radiology networks to identify and prioritize non-contrast head CT (NCCT) scans based on algorithmically-identified findings of acute intracranial hemorrhage (alCH). The device, which utilizes deep learning technologies, facilitates prioritization of CT scans containing findings of alCH. Accipiolx receives CT scans identified by the Accipio Agent or other compatible Medical Image Communications Device (MICD), processes them using algorithmic methods involving execution of multiple computational steps to identify suspected presence of alCH, and generates a results file to be transferred by the Accipio Agent or a similar MICD device for output to a PACS system or workstation for worklist prioritization.
Accipiolx works in parallel to and in conjunction with the standard care of workflow. After a CT scan has been performed, a copy of the study is automatically retrieved and processed by Accipiolx. The device performs identification and classification of objects consistent with alCH, and provides a case-level indicator which facilitates prioritization of cases with potential acute hemorrhagic findings for urgent review.
Intended Use / Indications for Use
Accipiolx is a software workflow tool designed to aid in prioritizing the clinical assessment of adult non-contrast head CT cases with features suggestive of acute intracranial hemorrhage in the acute care environment. Accipiolx analyzes cases using an artificial intelligence algorithm to identify
4
suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage.
Accipiolx is not intended to direct attention to specific portions of an image or to anomalies other than acute intracranial hemorrhage. Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out hemorrhage or otherwise preclude clinical assessment of CT cases.
Summary of Technological Characteristics
The technological characteristics and principles of operation of the subject Accipiolx device are substantially equivalent to the predicate device, Accipiolx (K182177). The subject Accipiolx and its predicate are DICOM-compliant software devices incorporated into the radiology infrastructure of a clinical center. Both employ algorithms developed through artificial intelligence methodologies to analyze head CT images received from a CT scanner.
The subject Accipiolx, like its predicate device, was developed using a training CT cases collected from multiple institutions and CT manufacturers. This training process included pilot development, optimization of object and feature identification, algorithmic training and selection/optimization of thresholds above which cases are considered positive.
The subject device and the predicate device also have highly similar principles of operation: the software analyzes CT images and prioritizes cases for physician review when there is suspected alCH. In both the predicate and subject devices, the algorithm identifies applicable CT cases based on image parameters. In both devices, skull stripping and registration steps are performed, the relevant tissues are identified and segmented, and a feature identification process, which includes measures of hyperdensity compared to a pre-defined threshold, is performed. Findings above this threshold cause the software device to generate a case-level identifier which is used for prioritization of cases based on a suspected cerebrovascular finding. The system output is used for prioritization within radiological workflow and viewing systems. In both cases, the procedure is performed in parallel to and in conjunction with the standard processing of image and their availability for clinician assessment.
The algorithmic functionality of Accipiolx is substantially equivalent in all aspects to that of the predicate device and differs only with respect to the segmentation method used and inclusion of additional algorithmic features for enhanced detection of alCH. These improvement changes do not alter the safety and efficacy profile of the device.
The subject Accipiolx and the predicate device have the same intended use and indications for use. Both devices are assistive software tools, designed to analyze head CT images for findings suggestive of a pre-specified clinical condition -- specifically, alCH. Both the subject and predicate devices support the rapid assessment of alCH. For these reasons, the subject device is substantially equivalent to the predicate device.
5
A summary table comparing the key features of the subject and predicate devices is provided below.
| | Subject Device:
MaxQ Al Accipiolx | Predicate Device:
MaxQ Al Accipiolx
(K182177) |
|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use /
Indications for Use | Accipiolx is a software workflow
tool designed to aid in prioritizing
the clinical assessment of adult
non-contrast head CT cases with
features suggestive of acute
intracranial hemorrhage in the
acute care environment. Accipiolx
analyzes cases using an artificial
intelligence algorithm to identify
suspected findings. It makes case-
level output available to a
PACS/workstation for worklist
prioritization or triage.
Accipiolx is not intended to direct
attention to specific portions of an | Accipiolx is a software workflow
tool designed to aid in prioritizing
the clinical assessment of adult
non-contrast head CT cases with
features suggestive of acute
intracranial hemorrhage in the
acute care environment. Accipiolx
analyzes cases using an artificial
intelligence algorithm to identify
suspected findings. It makes case-
level output available to a
PACS/workstation for worklist
prioritization or triage.
Accipiolx is not intended to direct
attention to specific portions of an |
| | image or to anomalies other than
acute intracranial hemorrhage. Its
results are not intended to be used
on a stand- alone basis for clinical
decision-making nor is it intended
to rule out hemorrhage or
otherwise preclude clinical
assessment of CT cases. | image or to anomalies other than
acute intracranial hemorrhage. Its
results are not intended to be used
on a stand- alone basis for clinical
decision-making nor is it intended
to rule out hemorrhage or
otherwise preclude clinical
assessment of CT cases. |
| Population | Adult patients (21 years of age and
older) indicated for head CT | Adult patients (21 years of age and
older) indicated for head CT |
| Notification-only, parallel workflow
tool | Yes | Yes |
| Intended users | Hospital networks and trained
clinicians | Hospital networks and trained
clinicians |
| Setting | Acute care | Acute care |
| Identify patients with a pre-
specified clinical condition | Yes | Yes |
| Clinical condition | Cerebrovascular Event:
Intracranial hemorrhage | Cerebrovascular Event:
Intracranial hemorrhage |
| Alert to finding | Yes; flagged for review | Yes; flagged for review |
| Independent of standard of care | Yes; No cases are removed from | Yes; No cases are removed from |
| workflow | worklist | worklist |
| Modality | Non-Contrast head CT | Non-Contrast head CT |
| Artificial Intelligence algorithm | Yes | Yes |
| Software segmentation method | CNN-based segmentation | Machine-vision based segmentation |
| Case level assessment of clinical
condition probability | Yes - case-level assessment is
derived both from detection of
individual aICH findings and
algorithmic assessment of the full
case. | Yes - case-level assessment is
derived from detection of individual
aICH findings |
6
| Limited to analysis of imaging data | Yes | Yes |
|---|---|---|
| Non-Diagnostic DICOM Preview | No | No |
| Aids prompt identification and | ||
| prioritization of cases with | ||
| indicated findings | Yes | Yes |
| Medical systems/devices used in | ||
| conjunction with the device | 1. Device is used with CT systems | |
| for DICOM input and with PACS | ||
| systems, which may present/use | ||
| the data. |
- Device is used with Medical
Image Communications Devices
(MICDs), such as the Accipio
Agent, to receive native CT
images for processing and to
generate visual results | 1. Device is used with CT systems
for DICOM input and with PACS
systems, which may present/use
the data. - Device is used with Medical
Image Communications Devices
(MICDs), such as the Accipio
Agent, to receive native CT
images for processing and to
generate visual results |
| Output | Suspected hemorrhage /
No suspected hemorrhage | Suspected hemorrhage /
No suspected hemorrhage |
| Systems where results are
displayed | PACS / Workstation | PACS / Workstation |
| Performance results | Sensitivity- 97%
(95% Cl: 92.8% - 98.8%)
Specificity- 93%
(95% Cl: 88.6% - 96.6%)
Processing time - 1.17 minutes
(95% Cl: 1.16 - 1.18 minutes) | Sensitivity - 92%
(95% Cl: 87.29 - 95.68%)
Specificity - 86%
(95% Cl: 80.18 - 90.81%)
Processing time - 4.1 minutes
(95% Cl: 3.8 - 4.3 minutes) |
Performance Testing
Performance testing was conducted using the same approach as that used for the predicate device. MaxQ AI conducted a retrospective study to test the clinical performance of Accipiolx in processing non-contrast head CT cases with a high or low probability of ICH. Performance of the device was analyzed based on validation testing results that were compared to the predefined performance qoals.
- . Analysis of 360 newly tested cases collected from multiple sites across 17 US states demonstrated device Sensitivity and Specificity of 97% (95% Cl: 92.8%) and 93% (95% Cl: 88.6% - 96.6%), respectively.
- Sensitivity for intra-axial and extra-axial hemorrhages was 100% (95% Cl: 96.6% 100%) and . 92% (95% Cl: 82.7% - 96.9%), respectively. Although the Sensitivity observed in the extra-axial subgroup was lower compared to the intra-axial subgroup, the result was still notably high, considering the fact that extra-axial hemorrhages are known to be more difficult for accurate assessment among radiologists.
- The average per-case processing time (confirmatory secondary endpoint) was 1.17 minutes (95% Cl: 1.16 - 1.18 minutes), demonstrating that when using the subject Accipiolx for alCH prioritization, the intended users will have improved benefit in time saving compared to the predicate device.
7
- Analysis of additional accuracy parameters, tested as secondary endpoints, demonstrated NPV . and PPV of 99.8% (95% Cl: 99.7% - 100%) and 43.3% (95% - 53%), respectively, The very high NPV result reflects relatively very low probability of false positive results given by Accipiolx.
These results exceeded the predefined performance goals and demonstrated improved clinical performance, which is substantially equivalent to the predicate device.
Based on the software testing and clinical performance, Accipiolx has a safety and effectiveness profile that is substantially equivalent to the predicate device for the proposed indications for use.
Conclusion
The Accipiolx device is as safe and effective as its predicate device. Accipiolx has the same intended use and indications for use, very similar technological characteristics and principles of operation as its predicate device. The minor differences do not alter the intended prioritization and triage use of the device and do not affect its safety and effectiveness when used as labeled, and also do not raise any new or different questions of safety or effectiveness. Clinical testing demonstrates an improved performance profile and supports the intended software function. Thus, the subject Accipiolx is substantially equivalent to the predicate Accipiolx (K182177).